6 Analysts Assess LifeStance Health Gr: What You Need To Know
6 analysts have shared their evaluations of LifeStance Health Gr (NASDAQ:LFST) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 2 | 0 | 0 | 0 |
| Last 30D | 2 | 1 | 0 | 0 | 0 |
| 1M Ago | 1 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $10.0, a high estimate of $12.00, and a low estimate of $8.00. This upward trend is apparent, with the current average reflecting a 8.7% increase from the previous average price target of $9.20.
Exploring Analyst Ratings: An In-Depth Overview
A clear picture of LifeStance Health Gr's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Richard Close | Canaccord Genuity | Raises | Buy | $10.00 | $9.00 |
| Kevin Caliendo | UBS | Raises | Buy | $12.00 | $10.00 |
| Scott Schoenhaus | Keybanc | Raises | Overweight | $9.00 | $8.00 |
| David Larsen | BTIG | Raises | Buy | $11.00 | $10.00 |
| David Larsen | BTIG | Raises | Buy | $10.00 | $9.00 |
| Peter Warendorf | Barclays | Announces | Overweight | $8.00 | - |
Key Insights:
- Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to LifeStance Health Gr. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of LifeStance Health Gr compared to the broader market.
- Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of LifeStance Health Gr's stock. This examination reveals shifts in analysts' expectations over time.
For valuable insights into LifeStance Health Gr's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
Stay up to date on LifeStance Health Gr analyst ratings.
Discovering LifeStance Health Gr: A Closer Look
LifeStance Health Group Inc is a mental healthcare company that operates as a provider of outpatient mental health services, spanning psychiatric evaluations and treatment, psychological and neuropsychological testing, and individual, family and group therapy. The group y has a single operating and reportable segment of mental health services.
Understanding the Numbers: LifeStance Health Gr's Finances
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Positive Revenue Trend: Examining LifeStance Health Gr's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 16.34% as of 30 September, 2025, showcasing a substantial increase in top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 0.3%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): LifeStance Health Gr's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 0.07%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): LifeStance Health Gr's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.05%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.31, LifeStance Health Gr adopts a prudent financial strategy, indicating a balanced approach to debt management.
Understanding the Relevance of Analyst Ratings
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
This article was generated by Benzinga's automated content engine and reviewed by an editor.